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infections at a South African children’s
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Abstract
Background: Klebsiella pneumoniae (KP) is a significant paediatric bloodstream pathogen in children. There is little
data from Africa. In this study we describe the epidemiology of multi-drug resistant Klebsiella pneumoniae
bloodstream infection (KPBSI) at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa.
Methods: We conducted a retrospective cross-sectional study of KPBSI from 1 January 2006 to 31 December 2011
using conventional descriptive and inferential statistical methods.
Results: Of 410 hospitalised children with laboratory confirmed KPBSI, 339 (83 %) were caused by extended-
spectrum β-lactamase (ESBL) producing isolates. The median age (IQR) was 5.0 (2–16) months, 212 (51.7 %) were
male, 82 (20 %) were HIV-infected, and 241 (58.8 %) were moderately or severely underweight. The infection was
hospital-acquired or healthcare-associated in 389 (95 %) children and community-acquired in 21 (5 %) children.
Significant risk factors for ESBL-KPBSI included cephalosporin exposure in the 12 months prior to the KPBSI, adjusted
risk ratio (aRR) 1.18 (95 % CI: 1.06–1.31); HIV infection, aRR 1.14 (1.04–1.25), and intravenous infusions for more than
3 days before the KPBSI, aRR 1.15 (95 % CI: 1.04–1.28).
A total of 109 (26.6 %) children died within 30 days of the KPBSI, their median age was four (IQR 1–11) months. The
median (IQR) time between KPBSI and death was three (1–9) days. HIV-infection, aRR 2.44(95 % CI: 1.59–3.74); skin
erosions at the time of KPBSI, aRR 2.15 (95 % CI: 1.54–3.00); being in PICU at the time of the KPBSI, aRR 1.64 (95 %
CI: 1.03–2.61) or needing PICU admission after developing KPBSI, aRR 1.72 (95 % CI: 1.10–2.70) were significant risk
factors for death.
Conclusion: ESBL-producing KP is an important cause of laboratory confirmed bloodstream infection in
hospitalised children and is associated with high mortality.
Keywords: Klebsiella pneumoniae bloodstream infection, Children, Africa
Background
Klebsiella pneumoniae (KP) is a significant bloodstream
pathogen resulting in major treatment and cost chal-
lenges for health institutions [1]. There is little data on
children from Africa where the effects of socioeconomic
inequalities and inadequate healthcare delivery remain
challenging and influence the outcome of infectious
diseases.
International reports show that extended-spectrum β-
lactamase (ESBL) producing Gram-negative bloodstream
infections (BSI) occur mainly in the setting of hospital ex-
posure. Reported risk factors for ESBL-strain acquisition
in paediatric Gram-negative BSI including KP include
prior cephalosporin exposure [2–6], prior hospitalisation
[3, 5], prolonged hospitalisation [7], previous corticoster-
oid use [2, 6], prolonged total parenteral nutrition [8],
paediatric intensive care unit (PICU) admission [3], pres-
ence of a central venous pressure (CVP) line [6], neutro-
paenia [6], and underlying renal disease [4].
The outcome data from the limited number of paedi-
atric studies involving Gram-negative BSI including KP
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portray high mortality ranging from 12.9 to 36 % [2–5,
7–10].
Over the last few years anecdotal observation suggested
that ESBL-producing KP frequently caused invasive infec-
tion at our hospital. We therefore reviewed laboratory-
confirmed KPBSI from 1 January 2006 to 31 December
2011 to document the extent of the problem at our hos-
pital. The specific objectives of the study were to describe
the clinical presentation of KPBSI, risk factors associated
with ESBL-KPBSI, antibiotic susceptibility patterns of the
KP isolates and KPBSI mortality including factors associ-
ated with in-patient mortality.
Methods
Study design and setting
This hospital based retrospective case folder review was
conducted at Red Cross War Memorial Children’s Hos-
pital (RCWMCH), Cape Town, Western Cape province,
South Africa. RCWMCH is a 282- bedded public chil-
dren’s hospital for children aged 0–13 years; it is also an
academic teaching hospital of the University of Cape
Town and is one of two local tertiary referral units that
service 1.5 million children <14 years of age in the West-
ern Cape. An average of 3500 new children per month
(range 3000 to 6000 per month) are evaluated in its med-
ical emergency unit, and the total number of hospital ad-
missions peaks at 23 000 children per annum. There is a
20-bedded multidisciplinary PICU, an 18-bed burn unit,
13-bed oncology unit, 60 mixed surgical beds, 58 general
paediatric beds; 29-bed cardiology and tracheostomy
ward, 29 specialty medical beds, 10-bed trauma unit and
42 short stay medical beds. Dedicated newborn care is
available at other hospitals in Cape Town where obstetric
care is provided. Admission numbers peak during diar-
rhoeal seasonal months (December to April) and over-
crowding commonly occurs throughout the hospital. The
main entry points into the hospital are via the medical
emergency or trauma units.
Study population
Most of the children admitted to RCWMCH come from
homes in low socioeconomic, peri-urban settlements in
the Western Cape Province. The Medical Microbiology
laboratory of the National Health Laboratory Service
(NHLS) identified and forwarded an electronic list of
Klebsiella pneumoniae bloodstream isolates identified
between 1 January 2006 and 31 December 2011 for chil-
dren admitted to RCWMCH.
Data collection
Data were collected from paper-based medical records in-
cluding patient demographics, admission diagnosis, HIV
and nutrition status, age, date of current hospital admis-
sion, underlying medical condition, previous medical
history, antibiotic history, site of KPBSI, potential risk fac-
tors for ESBL-KPBSI and mortality, length of hospital stay
and outcome.
Laboratory procedures
All microbiology testing was conducted at the Groote
Schuur National Health Laboratory Service (NHLS) micro-
biology laboratory. The laboratory used the BACTEC™
9240 automated blood culture system (Becton Dickinson,
Sparks, Maryland. For blood culture bottles flagging
positive with mono-morphic Gram-negative bacilli seen
on Gram stain, a locally validated method of direct inocu-
lation into the automated Vitek®2 system (bioMérieux,
Inc, France) was employed, [11] using Vitek® ID-GNB and
AST-N133 cards for identification and susceptibility test-
ing respectively. This direct method was supplemented,
where necessary with repeat testing from bacterial col-
onies subcultured onto agar plates, using either Vitek, disk
diffusion or E-test (bioMérieux, Marcy l’Etoile, France)
methods. The following antibiotics were tested: ampicillin,
co-amoxyclav, piperacillin-tazobactam, cefuroxime, cefoxi-
tin, ceftriaxone, ceftazidime, cefepime, ertapenem, mero-
penem, imipenem, ciprofloxacin, gentamicin, amikacin,
cotrimoxazole, tigecycline and colistin. Susceptibility re-
sults were interpreted according to the Clinical Laboratory
Standards Institute (CLSI) criteria for the relevant years
[12]. ESBLs were detected by the Vitek® 2 Advanced Ex-
pert system or by the double disk synergy method if using
disk diffusion testing. Despite the changes to reporting of
cephalosporin susceptibility in ESBL-producing organisms
introduced by CLSI in 2010, the laboratory, in line with
the contemporary national practice, continued to report
ESBL- producing Enterobacteriaceae as resistant to all
cephalosporins. Since ESBL production was not explicitly
reported on the laboratory information system (LIS) due
to limitations in the design and setup of the interface,
ESBL production was assumed if Klebsiella pneumoniae
isolates were reported to the clinicians (on the LIS) as re-
sistant to all cephalosporins.
Definitions
Hospital-acquired Klebsiella pneumoniae Blood Stream
infection (HA-KPBSI)
Klebsiella pneumoniae blood stream infection detected
48 h or more after hospital admission and not incubat-
ing at the time of hospitalisation [13].
Healthcare-associated (HCA)-KPBSI
Klebsiella pneumoniae blood stream infection detected
within 48 h of hospital admission in children who have
had contact with the healthcare service including admis-
sion to an intermediate care facility during the 12-month
period preceding hospitalisation. An intermediate facility
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provides step-down care for children recovering from
acute illness, for a maximum duration of 6 weeks [13].
Community-acquired (CA)-KPBSI
Klebsiella pneumoniae blood stream infection detected
within 48 h of hospital admission without previous contact
with the healthcare service.
ESBL-producing KP (ESBL KP)
Klebsiella pneumoniae isolates were classified as ESBL-
producing if they were resistant to cefepime [13].
HIV infection
A positive HIV DNA PCR result confirmed by either a
HIV RNA PCR or repeat HIV DNA PCR test, in any
child < 18 months old, or 2 positive serological test re-
sults (HIV ELISA or HIV Rapitest) or a positive HIV
DNA PCR result confirmed by either a HIV RNA PCR
or repeat HIV DNA PCR test, in a child > 18 months
old were considered HIV-infected [14].
Unknown HIV status
Any infant of child where there was no record of HIV
testing at the NHLS laboratory database and whose
mother’s HIV status was unknown.
Severe immunosuppression
A CD4 percentage and / or an absolute CD4 count below
the age defined range in an HIV-infected child, using the
2006 WHO definitions [15].
Nutritional status
Moderate and severe underweight were defined as weight-
for-age z score (WAZ) between −2 and −3 standard devia-
tions (SD) below the median World Health Organisation
(WHO) growth reference standards, and a WAZ < −3 SD
respectively.
Skin erosion
A burn wound or another form of skin loss (e.g. skin
loss as a consequence of severe napkin dermatitis) docu-
mented in the medical or nursing notes.
Data analysis
Clinical data were extracted retrospectively from the
hospital folders. Antibiotic sensitivity results were ob-
tained from the NHLS microbiology database. The data
were analysed using STATA Statistical software, release
11, (College Station, Texas, USA). Proportions were
depicted as percentages. Continuous variables were
tested for normality and mean and standard deviation
(SD) or median and interquartile range (IQR) used to
describe the data as appropriate. The Kruskal-Wallis
equality of populations’ rank test or Wilcoxon rank-sum
tests for independent samples were used to compare all
continuous variables. Factors associated with the outcome
risk of ESBL- infection or mortality were explored by
univariate analysis. Generalised linear models using
Poisson regression with robust error variance were used
to estimate risk ratios and 95 % confidence intervals
after controlling for potential confounding factors. A
two sided significance level of p < 0.05 was used in all
calculations. Infection risk was calculated per 1000
hospital admissions.
Results
Risk of Klebsiella pneumoniae bloodstream infections
Over the 6-year study period, 410 hospitalised children
had laboratory confirmed KPBSI, of whom 339 (83 %)
had ESBL-KPBSI. The infection was hospital-acquired
in 353, (86.1 %), healthcare-associated in 36, (8.8 %) or
community-acquired in 21, (5 %). The annual risk of
HA-KPBSI and ESBL-KPBSI increased from 2007,
peaking in 2009 and then declining in 2011 (Fig. 1).
Children hospitalised with CA-KP BSI were younger,
compared to those with HA- or HCA-KPBSI, median
age of 1.5 (IQR 0.7–3.8) months versus 5.5 (IQR 1.9–
16.2) months, p-value = 0.01.
Characteristics of the study population
The median age was 5.0 months (IQR 2 to 16 months),
198 were male and 212 female (Table 1). Two hundred
and forty one (58.8 %) children were moderately or
severely underweight-for-age (UWFA).
Two hundred and six (50.2 %) children were HIV
negative, 82 (20 %) were HIV-infected, and the HIV-
status was unknown in 122 (29.8 %) children. There
were more HIV-infected children with moderate or severe
UWFA compared to uninfected children, 61/82 (74.4 %),
versus 126/206 (61.2 %), p = 0.03. The CD4-lymphocyte
counts within the 3 month period preceding KPBSI were
known in 71/82 (86.6 %) of all HIV-infected children. The
median absolute CD4 count was 639 cells/mm3 (IQR 285
to 1235) and the mean CD4 percentage was 21.8 % (SD ±
12.33). Forty-two of 71 (59.2 %) HIV-infected children
were severely immunosuppressed by CD4 percentage-for-
age and 55/71 (77.5 %) severely immunosuppressed by
absolute CD4 count-for age. Forty-one (50 %) of the
eighty-two HIV-infected children were on antiretroviral
therapy (ART) at the time of the KPBSI. The median time
on ART before the KPBSI was 19 (IQR 8–66) days. The
annual proportion of children on ART increased progres-
sively over the study period (Fig. 2).
During the 12 month period preceding KPBSI, 40 %
(155/387) of the children had received antibiotics such as
2nd – 4th generation cephalosporins, fluoroquinolones,
macrolides, cotrimoxazole, aminoglycosides, piperacillin-
tazobactam, and/or carbapenems. Those who acquired
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ESBL-KPBSI had higher preceding antibiotic exposure
(Table 1). The median time from hospitalisation to KPBSI
was significantly shorter for children with non-ESBL-
KPBSI compared to those who developed ESBL-KPBSI, 3
(IQR 0–7) days versus 9 (IQR 4–23) days, p < 0.0001.
There were 29 (6.3 %) children who had either con-
firmed malignancy (26/29) or aplastic anaemia (3/29).
Their mean age was 69.6 months (SD ± 50.29) and
41.4 %(12/29) were male. The infection was HA-KPBSI
in 26/29 (90 %) children, caused by ESBL-producing KP
in all but 3 children and occurred in the neutropenic
phase in 20/29 (70 %) children. At the time of the KP-
BSI, their median white cell count was 0.6 × 109 /L (IQR
0.3–1.4).
Throughout the study period, HA-KPBSI caused by
ESBL-producing isolates predominated (Table 2).
Among children with CA-KPBSI, the number of ESBL-
producing isolates remained low. Furthermore, there
was a 47 % reduction in ESBL-KPBSI events between
2010 and 2011, from 63 to 37.
Spectrum of KP bloodstream infection
At the time of the KPBSI 70 % of children (284/405) ex-
perienced fever i.e., temperature of ≥38.0 °C. Although
there was a wide range of clinical manifestations at the
time of KPBSI, 80 % of the children either presented






























































































Fig. 1 Incidence risk of Klebsiella pneumoniae bloodstream
infection (KPBSI) per 1000 hospital admissions at RCWMCH January
2006- December 2011. Legend: ESBL-KPBSI: extended spectrum β-
lactamase producing Klebsiella pneumoniae bloodstream infection
Table 1 Characteristics of the children with Klebsiella pneumoniae bloodstream infection
Variable All ESBL-KPb Non-ESBL-KP p value
Number of children (%) N = 410 n = 339/410 (83 %) n = 71/410 (17 %) -
Male: female 212: 198 170: 169 1.77 0.17
Median (IQR) age in months 5 (2–16) 5 (2–5) 10 (2–29) 0.12
Median weight-for-age z-score (IQR) −2 (−4 to −1) −2 (−4 to −1) −1 (−3 to −1) 0.02
Moderate under-weight-for-age
n/N (%)
78/410 (19.0) 66/339 (19.5) 12 /71 (16.9) 0.14
Severe underweight-for-age n/N (%) 163/410 (39.8) 143/339 (42.2) 20 /71 (28.2) 0.01
HIV-infectiona (%) (n = 288) (n = 249) (n = 39)
82 (28.5) 79 (31.7 %) 3 (7.7 %) 0.004
Exposure to a selection of antibioticsc 319/388 (82.2) 287/319 (90) 31/68 (46.4) <0.0001
2nd - 4th generation Cephalosporins 205/388 (52.8) 190/205 (92.8) 15 /69 (17.8) <0.0001
Aminoglycosides 227/388 (58.5) 206/319 (64.6) 21/69 (30.4) <0.0001
Cotrimoxazole 96/388 (24.7) 91/319 (28.5) 5/69 (7.3) 0.001
Carbapenems 69/388 (17.8) 65/319 (20.4) 4 /69 (5.8) 0.004
Piperacillin-tazobactam 107/388 (27.6) 95/319 (29.8) 12/69 (17.4) 0.04
Fluoroquinolones 55/388 (14.2) 48/319 (15.1) 7/69 (10.1) 0.29
KP Klebsiella pneumoniae, IQR interquartile range, n/N stratum specific proportions
aHIV prevalence known in 288 children
bESBL-KP: extended-spectrum-β-lactamase-producing Klebsiella pneumoniae
cExposure to the following antibiotics within the last 12 months before the KP bloodstream infection: 2nd and/or 3rd and/or 4th generation cephalosporins,
macrolides, fluoroquinolones, cotrimoxazole, aminoglycosides, piperacillin-tazobactam, and carbapenems
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Risk factors for ESBL-associated KP infection
More children with ESBL-KPBSI were moderately or se-
verely underweight than those who had non-ESBL
KPBSI, i.e., 61.7 % (209/339) versus 45.1 % (32/71); p =
0.01; RR 1.13 (95%CI 1.02–1.24). Univariate analysis
showed that infancy, concomitant HIV infection, ceph-
alosporin exposure during the preceding 12 month
period, mechanical ventilation prior to BSI, intravenous
infusion for more than 3 days before the onset of KPBSI,
an indwelling urinary catheter prior to KPBSI, major
surgical procedure preceding KPBSI and a KP infection
in the 12 months preceding the current KPBSI were sig-
nificant risk factors for ESBL-KPBSI. On multivariate
analysis HIV infection, cephalosporin exposure in the
12 month period before the KPBSI and continuous
intravenous infusion for more than 3 days before the
KPBSI remained significant risk factors for the acquisi-
tion of ESBL-KPBSI (Table 4).
Antibiotic sensitivity profile of the isolates
All isolates, both ESBL- (n = 339) and non-ESBL-
producing (n = 71) were resistant to ampicillin. Of all iso-
lates tested, 21 % (86/409) were sensitive to gentamicin,
76.1 % (312/410) were sensitive to amikacin, 60.5 % (211/
349) were sensitive to piperacillin-tazobactam, and 29.1 %
(117/402] were sensitive to co-amoxyclav. All isolates were
sensitive to the carbapenems imipenem (409/409 tested)
and meropenem (409/409 tested), and 99.5 % [403/405)
were sensitive to ertapenem. The disaggregated antibiotic
sensitivity patterns of the KP isolates are shown in
Table 5.
Of the 82 HIV-infected children, 38 (46.3 %) were on
cotrimoxazole prophylaxis prior to the KPBSI and
96.3 % of their isolates (79/82) were ESBL-producing
organisms. All (38/38) isolates of HIV-infected children
on cotrimoxazole prophylaxis were resistant to cotri-
moxazole as well as 37/39 (97 %) isolates of those who
were not on cotrimoxazole prophylaxis. In 29 children
with malignancy or aplastic anaemia, 20/29 (70 %) iso-
lates were sensitive to piperacillin and/or amikacin.
Antibiotic therapy
Data on antibiotic therapy were available for 398 chil-
dren. Antibiotic therapy was considered appropriate if
the laboratory reported the organism as susceptible to
the specific antibiotic and suboptimal if the organism
was reported as being intermediately susceptible or re-
sistant. Empiric antibiotic therapy was appropriate in
307/398 (77.1 %) children comprising 241/328 (73.5 %)
children with ESBL KPBSI and 66/70 (94.3 %) children
with non-ESBL KPBSI. Piperacillin plus amikacin was
the empiric antibiotic choice in 18/29 (62 %) children
with malignancy or aplastic anaemia whilst 7/29 (24 %)
received a carbapenem; 25/29 (86 %) children received
a carbapenem as the definitive antibiotic. Once anti-
biotic susceptibility results became available, antibiotic
therapy was adjusted in patients in whom empiric ther-
apy was suboptimal. This delay did not alter the 30 day
mortality significantly i.e. 26.4 % (74/280) of children
on appropriate empiric therapy died versus 35.3 % (30/
















































Fig. 2 The number and percentage of HIV-infected children per
annum with KP BSI on ART during the study period, 2006–2011.
Legend: KP BSI-Klebsiella pneumoniae bloodstream infection;
ART-Antiretroviral therapy
Table 2 Number and percentage of non-ESBL producing and ESBL producing Klebsiella pneumoniae BSI within each infection
category 2006–2011















2006 3 (4.3) 2 (2.9) 46 (65.7) 14 (20.0) 1 (1.4) 4 (5.7) 70 (17)
2007 0 3 (6.0) 38 (76.0) 3 (6.0) 4 (8.0) 2 (4.0) 50 (12)
2008 3 (4.1) 0 59 (80.8) 6 (8.2) 2 (2.7) 3 (4.1) 73 (18)
2009 1 (1.2) 4 (4.7) 68 (79.1) 4 (4.7) 8 (9.3) 1 (1.2) 86 (21)
2010 0 2 (2.5) 63 (78.8) 8 (10.0) 3 (3.8) 4 (5.0) 80 (20)
2011 0 3 (5.9) 37 (72.6) 7 (13.7) 3 (5.9) 1 (2.0) 51 (12)
Totals 7 (1.7) 14 (3.4) 311 (76.0) 42 (10.0) 21 (5.1) 15 (3.7) 410 (100)
ESBL KPBSI extended-spectrum-β-lactamase-producing Klebsiella pneumoniae bloodstream infection, BSI bloodstream infection
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KPBSI mortality
One hundred and twenty-three of the 410 study children
died over the 6 year period, giving a crude case fatality
rate of 30 %. Only the children dying within 30 days of
the KPBSI (109/410, 26.6 %) were included in the mor-
tality analysis as there was higher chance of identifying
factors associated with KPBSI mortality in these chil-
dren. Deaths occurring beyond this time period were
deemed unlikely to be related to the KPBSI. The mean
time to death from KPBSI diagnosis of the 14 children
who died after 30 days was 46.4 (SD ±11.2) days. Among
the 109 patients dying within 30 days, the median time
to death (n = 109) was 3 days (IQR 1–9 days) (Table 6).
One hundred (91.7 %) of the deaths were associated with
ESBL-KPBSI. In 37.6 % (41/109) children the deaths oc-
curred in children with ESBL KPBSI without a definable
focus and 41.3 % (45/109) occurred in children who
manifested with pneumonia. The KPBSI was community
acquired in four (3.7 %) children who died, two of whom
had non-ESBL KP isolates. Hospital-acquired (92/109,
84.4 %) and healthcare-associated (13/109, 11.9 %)
KPBSI accounted for the rest of the mortality. Of the
children who died 70.6 % (77/109) had a chronic under-
lying medical disorder, most commonly HIV infection
(37 children), congenital cardiac conditions (11 children)
and gastrointestinal conditions (14 children).
Factors contributing to 30-day mortality on univariate
analysis included ESBL KPBSI, HIV infection, KPBSI re-
quiring admission to PICU, and the presence of skin
erosions, while KPBSI without a source had a protective
effect. On multivariate analysis HIV infection, being in
the PICU at the time of the BSI, KPBSI requiring admis-
sion to PICU, and the presence of skin erosions were
significant risk factors for death (Table 7).
Discussion
In this hospital based retrospective study we have
described laboratory-confirmed Klebsiella pneumoniae
bloodstream infections in children admitted to RCWMCH
from 1 January 2006–31 December 2011. This is the first
Table 3 The clinical site of infection in children with Klebsiella
pneumoniae bloodstream infection
Clinical site of infection All ESBL Non-ESBL p value
n/N (%) n/N (%) n/N (%)
No. with primary
bloodstream infection








Common sites of infection
Pneumonia 122 (29.8) 108 (31.9) 14 (19.7) 0.04
Vascular-catheter related 20 (4.9) 19 (5.6) 1 (1.4) 0.13
Peritonitis 20 (4.9) 16 (4.7) 4 (5.6) 0.76
UTIa 20 (4.9) 16 (4.7) 4 (5.6) 0.76
Septic wound and soft
tissue
23 (5.7) 21 (6.2) 2 (2.8) 0.26
NECb 20 (4.9) 18 (5.3) 2 (2.8) 0.37
Septic drip site
(+vec culture of KP)
12 (2.9) 11 (3.2) 1 (1.4) 0.4
Cholangitis 4 (1.0) 4 (1.2) 0 N/S
Dysentery 3 (0.7) 2 (0.6) 1 (1.4) 0.4
Typhilitis 3 (0.7) 3 (0.9) 0 N/S
Bacterial endocarditis 1 (0.2) 1 (0.3) 0 N/S
Necrotic tumour 1 (0.2) 1 (0.3) 0 N/S
Bowel obstruction 1 (0.2) 1 (0.3) 0 N/S
n/N stratum specific proportions, UTIa urinary tract infection, NECb, necrotising
enterocolitis, +vec positive, ESBL extended-spectrum-β-lactamase-producing
Klebsiella pneumoniae
Table 4 Factors associated with ESBL-Klebsiella pneumoniae bloodstream infection (BSI)
Risk factors for ESBL KPBSI ESBL Non-ESBL Univariate analysis Adjusted analysis (n = 271)
n/N (%) n/N (%) RRa (95 % CI) p-value RR (95 % CI) p-value
Moderate or severe underweight for age 209/339 (61.7) 32/71 (45.1) 1.13 (1.02–1.24) 0.01 0.99 (0.97–1.01) 0.40
HIV-infection 79/249 (31.7) 3/39 (7.7) 1.22 (1.13–1.30) <0.001 1.14 (1.04–1.25) 0.01
Patient in the PICUb 92/339 (27.1) 11/71 (15.5) 1.11 (1.02–1.21) 0.04 0.99 (0.88–1.12) 0.94
Cephalosporin exposure in the last 12 months pre-BSI 184/339 (54.3) 12/71 (16.9) 1.30 (1.18–1.42) <0.001 1.18 (1.06–1.31) 0.002
Mechanical ventilation prior to BSI 142/335 (42.4) 13/71 (18.3) 1.19 (1.10–1.29) <0.001 1.08 (0.93–1.24) 0.31
Continuous infusion for >3 days prior to BSI 247/334 (74.0) 30/71 (42.3) 1.31 (1.16–1.49) <0.001 1.15 (1.04–1.28) 0.009
Indwelling urinary catheter prior to BSI 139/335 (41.5) 12/71 (16.9) 1.20 (1.10–1.30) <0.001 1.09 (0.99–1.20) 0.10
Major surgical procedure prior to BSIc 115/336 (34.2) 16/71 (22.5) 1.10 (1.01–1.20) 0.04 1.06 (0.95–1.18) 0.33
Skin erosions 111/336 (33.0) 19/71 (26.8) 1.05 (0.96–1.15) 0.30 1.07 (0.98–1.17) 0.12
Previous KP infection within last 12 months 39/338 (11.5) 3/71 (4.2) 1.14 (1.03–1.26) 0.01 0.96 (0.84–1.11) 0.62
Multivariable model adjusted for gender, age, HIV infection, underweight-for-age, mechanical ventilation, patient in the PICU at the time of the BSI, continuous IV
infusion for more than 3 days before the BSI, indwelling urinary catheter, major surgery before the BSI, Previous KP infection within last 12 months, skin erosions
and cephalosporin exposure during last 12 months before the BSI. aRR adjusted risk ratio
ESBL-KP extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, BSI bloodstream infection
aRR risk ratio; bPICU: paediatric intensive care unit; c A major surgical procedure included a laparotomy (emergency or elective), a thoracotomy, a skin graft or a
craniotomy; Risk ratio 95 % confidence intervals that do not cross the null value of 1 are shown in bold
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comprehensive analysis of Klebsiella pneumoniae blood-
stream infections in hospitalised children at a dedicated
children’s hospital in Sub-Saharan Africa. This study
showed that ESBL- Klebsiella pneumoniae is an important
cause of HA- and HCA-BSI and is associated with high
mortality.
Notably 68.9 % of the children were less than 12 months
old. In the only other large published paediatric case series
on KPBSI that involved 57 American children, infancy was
also the predominant age-category i.e., 68 % (n = 38/57) of
the children were less than 12 months [10]. Young chil-
dren, particularly infants, are not fully immunocompetent
and more susceptible to bacterial infections including
KPBSI. Young age and immunological immaturity may
also contribute to the delayed diagnosis of sepsis [16]. A
high prevalence of moderate and severe underweight,
an indicator of malnutrition was documented. On uni-
variate analysis moderate or severe underweight-for-age
was more frequent in children with ESBL-KPBSI (209/
339, 61.7 %) compared to those with non-ESBL KPBSI
(32/71, 45.1 %); p = 0.01. Malnutrition is known to be
associated with widespread micronutrient deficiencies,
immune dysfunction, and susceptibility to infectious
complications [17].
The study population was representative of the children
living in the Western Cape region, coming mainly from
peri-urban, low socio-economic sub-districts. National
figures show that the incidence of under-weight-for-age
(UWFA) in children <5 varied from 16/1000 (2012) to 22/
1000 (2009) and that the incidence of severe acute malnu-
trition was 4-5/1000 (2009–2012) [18]. The 2011 national
Census established that 40 % of 5 million South African
children <5 years-of-age were UWFA and that there was a
high incidence of stunting (26.9 %) in children <3 years-of
age [19, 20]. Concomitant HIV infection is known to be a
significant contributor to malnutrition and was present in
20 % of the study children.
At the time of the positive blood culture 30 % (126/
410) of the study children did not experience fever and
50.2 % had no definable clinical focus. When a focus
was present this was commonly in the lungs. In a paral-
lel study on Staphylococcus aureus bloodstream infection
at our hospital, 33 % of children had no identifiable
source and, where one was identified, the lungs were
the most common focus (22 %) [21]. In another paedi-
atric study describing BSIs caused by of Gram-negative
pathogens including KP, the absence of a clear clinical
focus occurred in 68 % of the study subjects [6]. Unlike
a child presenting from home with a CA-BSI where the
clinical manifestations precipitate presentation to a
health facility, HA-BSI may manifest with non-specific
signs leading to delay in recognising active infection. Fur-
thermore, the decision to take blood cultures were made
by the caring clinicians based on clinical indications; given
the retrospective study design no attempt was made to in-
terrogate the possibility of blood culture contamination.
In the current study KPBSI was primarily a hospital-
acquired infection caused by ESBL-producing isolates.
Community-acquired infection was uncommon, particu-
larly community-acquired infection caused by ESBL-
producing isolates. These findings are similar to previous
studies describing Gram-negative BSI in children [6, 22].
Prior cephalosporin exposure increased the risk for
ESBL-KPBSI, confirming findings of previous paediatric
studies [2–5]. Two additional statistically significant risk
factors were identified. The risk of HIV infection prob-
ably relates to the underlying immunodeficiency, par-
ticularly as 50 % of the HIV-infected children were not
on ART at the time of acquiring KPBSI. The risk of con-
tinuous intravenous infusion for more than 3 days before
the BSI was diagnosed may result from poor infection
control practice and / or contamination of the infused
Table 5 Antibiotic susceptibility results of extended spectrum beta
lactamase (ESBL) and non-ESBL Klebsiella pneumoniae isolates
Antibiotic Number of resistant isolates
Non-ESBL KP ESBL KP
n/N (%) n/N (%)
Ampicillin 71/71 (100) 339/339 (100)
Co-amoxyclav 5/71 (7.1) 280/331 (84.6)
Cefotaxime 0/71 (0) 339/339 (100)
Ceftazidime 0/71 (0) 339/339 (100)
Cefepime 0/71 (0) 339/339 (100)
Ciprofloxacin 0/71 (0) 142/339 (41.9)
Cotrimoxazole 18/71 (25.4) 313/339 (92.3)
Amikacin 0/71 (0) 98/339 (28.9)
Gentamicin 4/71 (5.6) 319/338 (94.4)
Piperacillin-Tazobactam 2/67 (3.0) 136/282 (48.2)
Ertapenem 0/67 (0) 2/338 (0.6)
Imipenem 0/71 (0) 0/338 (0)
Meropenem 0/71 (0) 0/338 (0)
KP Klebsiella pneumoniae, ESBL KPBSI Extended-spectrum-beta-lactamase-
producing Klebsiella pneumoniae bloodstream infection, co-amoxyclav
amoxicillin-clavulanic acid co-formulation, n/N stratum specific proportions
Table 6 Time to death in 3 time categories in study children with
Klebsiella pneumoniae bloodstream infection
Cause of death Time to death from KPBSI
≤3 days 3.1–14 days 14.1–30 days Totals
n (%) n (%) n (%) n (%)
Septicaemia 48 (44.0) 28 (25.7) 8 (7.3) 84 (77.1)
Pneumonia 6 (5.5) 4 (3.7) 5 (4.6) 15 (13.8)
Other 3 (2.8) 5 (4.6) 2 (1.8) 10 (9.1)
Totals 57 (52.3) 37 (33.9) 15 (13.8) 109 (100)
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fluid during intravenous drug administration. Published
studies have implicated these factors, but no paediatric
study has previously shown a statistical relation between
BSI and prior intravenous infusion on multivariate ana-
lysis [23, 24].
At the time of the study, empiric antibiotic therapy at
RCWMCH for CA-BSI was ampicillin plus gentamicin
and for HA- and HCA-BSI, piperacillin-tazobactam
plus amikacin. These empiric regimens were also ap-
plied to children who had malignancy or aplastic an-
aemia. The study findings suggest that these empiric
antibiotic combinations would not have been effective
against 22.9 % of non-susceptible isolates, intermediate
or resistant, in patients with KPBSI. Once antibiotic
susceptibility results were made available to the attend-
ing clinicians these patients were started on effective
antibiotic therapy, and the resultant delay did not sig-
nificantly affect 30-day mortality. However, the low
cover for HA- and HCA-BSI suggest that more effect-
ive empiric antibiotic therapy using a carbapenem
should be considered. This suggestion concurs with
previous studies [3, 5]. During the study period there
was full access to all classes of appropriate antibiotics
that were reported by the NHLS microbiology labora-
tory including ertapenem, imipenem and meropenem.
There was a notable surge and decrease in the risk of
ESBL-producing KP HA-infection over 2009 and 2010.
The impact of a South African measles epidemic starting
in the Western Cape Province in 2009, peaking during a
diarrhoeal surge season in March and April of 2010 and
then abating in November of the same year was associ-
ated with severe pressure on beds and subsequent over-
crowding in all wards of the hospital, this may have
accounted for the surge seen. The falling trend in the
risk thereafter at the hospital may well also reflect some
success of the preventive strategy package driven by the
hospital infection control unit e.g., increased awareness
of the importance of hand hygiene, training on how to
perform hand hygiene and an effort to reduce over-
crowding in certain key areas of the hospital.
The impact of Gram-negative bacteraemia is signifi-
cant in children with reduced immunity, including those
with cancer, and access to carbapenem antibiotics is im-
portant particularly as the control of sepsis during fe-
brile neutropenic episodes is time-critical.
The high 30-day fatality rate of 26.6 % and with
52.3 % of the deaths occurring within 3 days of the
positive blood culture result were consistent with previ-
ous paediatric studies of Gram-negative BSI including
KP where mortality ranged from 13 to 36 % [2, 3, 8–10]
and a bacteraemia study in rural Kenya in which 70.5 %
of deaths occurred within 3 days of positive blood cul-
ture [25]. In the present study HIV infection, being in
the PICU at the time of BSI or needing PICU admission
and the presence of skin erosions were significant risk
factors for death. Previous paediatric studies have iden-
tified a different spectrum of independent risk factors
for death including the presence of an ESBL-producing
organism, shock on admission to hospital and more
than 48-h delay in initiating appropriate antibiotic ther-
apy, and in neonates infectious complications after the
onset of BSI and pulmonary hypertension. In the
present study, mortality was higher in children who re-
ceived suboptimal empiric antibiotic therapy (35.3 % vs
26.4 %). Although this difference appeared clinically
relevant, it did not achieve statistical significance, partly
because the analysis was underpowered on post-hoc
evaluation i.e., power of 36 % at an alpha of 0.05.
Table 7 Factors associated with 30-day inpatient mortality in children with Klebsiella pneumoniae bloodstream infection
Risk factors for death Alive Died Univariate analysis Adjusted RRa for mortality (n = 259)
n/N (%) n/N (%) RRa (95 % CI) p-value aRR (95 % CI) p-value
ESBL-KPBSI 210/267 (78.7) 100/109 (91.7) 2.36 (1.26–4.43) 0.00 1.09 (0.55–2.16) 0.80
Moderate or severe underweight-for-age 150/267 (56.2) 71/109 (65.1) 1.31 (0.94–1.83) 0.11 1.12 (0.79–1.62) 0.54
HIV-infection** 38/181 (21.0) 37/83 (44.6) 2.03 (1.44–2.85) <0.001 2.44 (1.59–3.74) <0.001
Patient in the PICU at time of BSI** 56/267 (21.7) 31/109 (28.4) 1.28 (0.91–1.80) 0.16 1.64 (1.03–2.61) 0.04
Patient needing to go to PICU at the time of KP
bloodstream infection**
44/267 (16.5) 34/109 (31.2) 1.73 (1.26–2.38) 0.001 1.72 (1.10–2.70) 0.02
Continuous IV infusion for >3 days before the BSI 174/264 (65.9) 73/108 (67.6) 1.06 (0.75–1.48) 0.76 0.93 (0.64–1.35) 0.70
BSI without source** 145/266 (54.5) 41/108 (38.0) 0.61 (0.44–0.86) 0.004 0.82 (0.55–1.22) 0.33
Chronic underlying medical condition excluding
HIV infection
124/267 (46.4) 41/109 (37.6) 0.77 (0.56–1.07) 0.12 1.30 (0.81–2.08) 0.28
Skin erosions** 70/265 (26.4) 47/108 (43.5) 1.69 (1.24–2.30) 0.001 2.15 (1.54–3.0) <0.001
n/N stratum specific proportions; **p-value ≤ 0.05; RR risk ratio
ESBL KP BSI Extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae bloodstream infection, PICU paediatric intensive care unit, aRR adjusted risk ratio
*:Multivariate model adjusted for age, gender, nutrition, HIV infection, ESBL, Patient in PICU, patient needing to go to PICU, continuous IV infusion for >3 days be-
fore the BSI, KPBSI without source, chronic underlying medical condition excluding HIV, and skin erosions
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Study strengths and limitations
A strength of this study is that it is the first large African
study to describe KPBSI in children, providing clinical and
epidemiological information which was not previously
available. Because of the retrospective study design, there
were limitations in the availability and completeness of
clinical and laboratory data. For example, the HIV status
of 122 children was not known because there was no
documentation of testing in the clinical notes or at the la-
boratory. Were these results available they would have in-
fluenced the risk factor analyses. One further strength of
the study was that the ESBL status of the KP isolates did
not influence the extraction of data from the folder review
because the study team were blinded to status at the time
of the data collection. The true burden of community-
acquired KPBSI, particularly non-ESBL KPBSI events may
have been underestimated. Before sick children are re-
ferred from primary or secondary health facilities to
RCWMCH, they are often administered parenteral broad-
spectrum antibiotics consistent with the World Health
Organization Integrated Management of Childhood Ill-
ness guidelines that have been adapted for use in South
Africa [26]. This practice frequently results in negative
blood culture results. Further, due to the retrospective
design the history and detail of exposure to previous hos-
pitalisation and antibiotics was limited to what was docu-
mented in the case folders by the admitting doctors and
any pharmacy prescription sheets that were available; any
outpatient exposures and admissions to hospitals other
than RCWMCH that were not recorded in the folders
were not captured and could have led to potential under
reporting as exposed to antibiotics. Because of the limita-
tions associated with laboratory reporting, for the pur-
poses of this study, KP was assumed to be an ESBL
producer if it was reported to clinicians as resistant to all
cephalosporins. The laboratory continued to report ESBL-
producing Enterobacteriaceae as resistant to all cephalo-
sporins, despite changes in reporting practices introduced
by CLSI in 2010, hence there may have been over report-
ing of cephalosporin resistance in the latter years. Due to
limitations in laboratory interfaces MIC data are not rou-
tinely available to clinicians.
Although the results of this study may not be
generalizable to other referral hospitals or community
facilities, they demonstrate that KPBSI is an important
childhood infection and substantially improved infec-
tion control practice is required to reduce the burden
of hospital-acquired KPBSI.
Conclusion
Multi-drug resistant Klebsiella pneumoniae bloodstream
infection is associated with high mortality in children.
Our analysis together with previous studies suggest that
this infection is strongly associated with hospitalisation.
Prospective studies are required to further explore the
clinical and epidemiological observations documented in
this study, and characterise the microbiological features
and relatedness of KP isolates causing BSI in our setting.
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